TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial
is designed to assess the safety and tolerability of induction talazoparib followed by
combination of talazoparib and avelumab. As an exploratory endpoint, the study team will
evaluate the immunomodulatory effects of induction talazoparib followed by the combination of
talazoparib and avelumab in patients with advanced breast cancer.